

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
1.11	09/28/2024	5360093-00012	Date of first issue: 12/19/2019

SECTION 1. IDENTIFICATION

Product name : Levamisole / Oxyclozanide Formulation
Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Reproductive toxicity : Category 2
Specific target organ toxicity : Category 2 (Central nervous system)
- single exposure (Oral)
Specific target organ toxicity : Category 2 (Brain, Liver)
- repeated exposure
Specific target organ toxicity : Category 2 (Blood, Testis)
- repeated exposure (Oral)

GHS label elements

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H361d Suspected of damaging the unborn child.
H371 May cause damage to organs (Central nervous system) if swallowed.
H373 May cause damage to organs (Brain, Liver) through prolonged or repeated exposure.
H373 May cause damage to organs (Blood, Testis) through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Levamisole / Oxyclozanide Formulation

Version 1.11 Revision Date: 09/28/2024 SDS Number: 5360093-00012 Date of last issue: 09/30/2023
Date of first issue: 12/19/2019

P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe mist or vapors.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:

P308 + P311 IF exposed or concerned: Call a doctor.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Kaolin	Hydrated aluminum silicate	1332-58-7	6
Oxyclozanide	3,3',5,5',6-Pentachloro-2'-hydroxysalicylanilide	2277-92-1	3
Levamisole hydrochloride	No data available	16595-80-5	1.5
Citric acid	2-hydroxypropane-1,2,3-tricarboxylic acid	77-92-9	1.37

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
1.11	09/28/2024	5360093-00012	Date of first issue: 12/19/2019

In case of eye contact	:	Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse. Flush eyes with water as a precaution.
If swallowed	:	Get medical attention if irritation develops and persists. If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.
Most important symptoms and effects, both acute and delayed	:	Suspected of damaging the unborn child. May cause damage to organs if swallowed. May cause damage to organs through prolonged or repeated exposure.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Chlorine compounds Nitrogen oxides (NO _x)
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Levamisole / Oxytocin Formulation

Version 1.11 Revision Date: 09/28/2024 SDS Number: 5360093-00012 Date of last issue: 09/30/2023
Date of first issue: 12/19/2019

Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation : Use only with adequate ventilation.
Advice on safe handling : Do not breathe mist or vapors.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.
Conditions for safe storage : Keep in properly labeled containers.
Store locked up.
Store in accordance with the particular national regulations.
Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Kaolin	1332-58-7	TWA (Res-	2 mg/m ³	CA AB OEL

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Levamisole / Oxyclozanide Formulation

Version 1.11 Revision Date: 09/28/2024 SDS Number: 5360093-00012 Date of last issue: 09/30/2023
Date of first issue: 12/19/2019

		pirable)		
		TWA (Respirable)	2 mg/m ³	CA BC OEL
		TWAEV (respirable dust)	2 mg/m ³	CA QC OEL
		TWA (Respirable particulate matter)	2 mg/m ³	ACGIH
Oxyclozanide	2277-92-1	TWA	0.4 mg/m ³ (OEB 2)	Internal
Levamisole hydrochloride	16595-80-5	TWA	20 µg/m ³ (OEB 3)	Internal
	Further information: Skin			
		Wipe limit	200 µg/100 cm ²	Internal

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Levamisole / Oxyclozanide Formulation

Version 1.11	Revision Date: 09/28/2024	SDS Number: 5360093-00012	Date of last issue: 09/30/2023 Date of first issue: 12/19/2019
-----------------	------------------------------	------------------------------	---

When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: liquid
Color	: No data available
Odor	: No data available
Odor Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapor pressure	: No data available
Relative vapor density	: No data available
Relative density	: No data available
Density	: No data available
Solubility(ies) Water solubility	: No data available
Partition coefficient: n-octanol/water	: Not applicable
Autoignition temperature	: No data available

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
1.11	09/28/2024	5360093-00012	Date of first issue: 12/19/2019

Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics		
Particle size	:	Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
---------------------	---	--

Components:

Kaolin:

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute dermal toxicity	:	LD50 (Rat): > 5,000 mg/kg

Oxyclozanide:

Acute oral toxicity	:	LD50 (Rat): 3,519 mg/kg Target Organs: Central nervous system
---------------------	---	--

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
1.11	09/28/2024	5360093-00012	Date of first issue: 12/19/2019

Acute toxicity (other routes of administration) : LDLo (sheep): 10 mg/kg
Application Route: Intravenous

Levamisole hydrochloride:

Acute oral toxicity : LD50 (Rat): 180 mg/kg
LD50 (Mouse): 223 mg/kg
LD50 (Rabbit): 458 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Citric acid:

Acute oral toxicity : LD50 (Mouse): 5,400 mg/kg
Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

Kaolin:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Oxyclozanide:

Remarks : Not classified due to lack of data.

Levamisole hydrochloride:

Remarks : No data available

Citric acid:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
1.11	09/28/2024	5360093-00012	Date of first issue: 12/19/2019

Components:

Kaolin:

Species	:	Rabbit
Result	:	No eye irritation

Oxyclozanide:

Remarks	:	Not classified due to lack of data.
---------	---	-------------------------------------

Levamisole hydrochloride:

Remarks	:	No data available
---------	---	-------------------

Citric acid:

Species	:	Rabbit
Result	:	Irritation to eyes, reversing within 21 days
Method	:	OECD Test Guideline 405

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Oxyclozanide:

Routes of exposure	:	Dermal
Remarks	:	Not classified due to lack of data.

Levamisole hydrochloride:

Remarks	:	No data available
---------	---	-------------------

Germ cell mutagenicity

Not classified based on available information.

Components:

Oxyclozanide:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive
		Test Type: Mouse Lymphoma Result: positive
Genotoxicity in vivo	:	Test Type: Micronucleus test

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
1.11	09/28/2024	5360093-00012	Date of first issue: 12/19/2019

Species: Mouse
Application Route: Oral
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
Application Route: Oral
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Levamisole hydrochloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Citric acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: in vitro micronucleus test
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Oxyclozanide:

Remarks : Not classified due to lack of data.

Levamisole hydrochloride:

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
NOAEL : 80 mg/kg body weight
Remarks : No significant adverse effects were reported

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Levamisole / Oxcyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
1.11	09/28/2024	5360093-00012	Date of first issue: 12/19/2019

Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
NOAEL	:	40 mg/kg body weight
Remarks	:	No significant adverse effects were reported

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Oxcyclozanide:

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat, male and female
Application Route: Oral
General Toxicity Parent: NOAEL: 25 - 35 mg/kg body weight
Symptoms: Reduced body weight, No effects on embryofetal and postnatal development.
Result: No effects on fertility.

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity Parent: LOAEL: 75 - 100 mg/kg body weight
Symptoms: Reduced body weight, No effects on embryofetal and postnatal development.
Result: No effects on fertility.

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Early Embryonic Development: LOAEL: 75 - 100 mg/kg body weight
Result: No fetotoxicity., No teratogenic effects.

Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity Parent: LOAEL: 80 - 160 mg/kg body weight
Result: No fetotoxicity., No teratogenic effects., No effects on fertility.

Effects on fetal development : Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 200 mg/kg body weight
Result: No fetotoxicity., No teratogenic effects.

Test Type: Development
Species: Rat
Application Route: Oral
General Toxicity Maternal: LOAEL: 100 mg/kg body weight
Result: No fetotoxicity., No teratogenic effects.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Levamisole / Oxytoclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
1.11	09/28/2024	5360093-00012	Date of first issue: 12/19/2019

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 32 mg/kg body weight
Result: Fetotoxicity., Skeletal malformations.

Reproductive toxicity - Assessment : Suspected of damaging the unborn child.

Levamisole hydrochloride:

Effects on fertility : Test Type: Three-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Result: No significant adverse effects were reported

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 20 mg/kg body weight
Result: Fetotoxicity.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 40 mg/kg body weight
Result: Fetotoxicity.

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

Citric acid:

Effects on fetal development : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

STOT-single exposure

May cause damage to organs (Central nervous system) if swallowed.

Components:

Oxytoclozanide:

Routes of exposure : Oral
Target Organs : Central nervous system
Assessment : May cause damage to organs.

Citric acid:

Assessment : May cause respiratory irritation.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Levamisole / Oxyκλοzanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
1.11	09/28/2024	5360093-00012	Date of first issue: 12/19/2019

STOT-repeated exposure

May cause damage to organs (Brain, Liver) through prolonged or repeated exposure.
May cause damage to organs (Blood, Testis) through prolonged or repeated exposure if swallowed.

Components:

Oxyκλοzanide:

Target Organs	: Brain, Liver
Assessment	: May cause damage to organs through prolonged or repeated exposure.

Levamisole hydrochloride:

Target Organs	: Blood, Testis
Assessment	: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Oxyκλοzanide:

Species	: Rat
NOAEL	: 9 mg/kg
LOAEL	: 44.5 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Brain, Liver, spleen, Adrenal gland
Symptoms	: Liver effects
Species	: Dog
NOAEL	: 5 mg/kg
LOAEL	: 25 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Brain, Liver
Symptoms	: blood effects, alteration in liver enzymes

Levamisole hydrochloride:

Species	: Rat
NOAEL	: 2.5 mg/kg
Application Route	: Oral
Exposure time	: 18 Months
Target Organs	: Testis
Species	: Dog
LOAEL	: 20 mg/kg
Application Route	: Oral
Exposure time	: 18 Months
Target Organs	: Blood

Species	: Dog
---------	-------

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Levamisole / Oxyκλοzanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
1.11	09/28/2024	5360093-00012	Date of first issue: 12/19/2019

LOAEL : 40 mg/kg
Application Route : Oral
Exposure time : 3 Months

Citric acid:

Species : Rat
NOAEL : 4,000 mg/kg
LOAEL : 8,000 mg/kg
Application Route : Ingestion
Exposure time : 10 Days

Aspiration toxicity

Not classified based on available information.

Components:

Oxyκλοzanide:

Not applicable

Experience with human exposure

Components:

Oxyκλοzanide:

Ingestion : Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression

Levamisole hydrochloride:

Ingestion : Symptoms: Nausea, Vomiting, Headache, Dizziness, hypotension

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Oxyκλοzanide:

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.69 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Levamisole hydrochloride:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 37.3 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 64 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
1.11	09/28/2024	5360093-00012	Date of first issue: 12/19/2019

Citric acid:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
Exposure time: 96 h

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 1,535 mg/l
aquatic invertebrates Exposure time: 24 h

Persistence and degradability

Components:

Oxyclozanide:

Stability in water : Hydrolysis: 50 %(156 d)
Method: OECD Test Guideline 111

Citric acid:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 97 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Bioaccumulative potential

Components:

Oxyclozanide:

Partition coefficient: n- : log Pow: 3.99
octanol/water pH: 7
Method: OECD Test Guideline 107

Citric acid:

Partition coefficient: n- : log Pow: -1.72
octanol/water

Mobility in soil

Components:

Oxyclozanide:

Distribution among environ- : log Koc: 4.83
mental compartments Method: OECD Test Guideline 106

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Levamisole / Oxytoclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
1.11	09/28/2024	5360093-00012	Date of first issue: 12/19/2019

handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxytoclozanide)
Class	:	9
Packing group	:	III
Labels	:	9
Environmentally hazardous	:	yes

IATA-DGR

UN/ID No.	:	UN 3082
Proper shipping name	:	Environmentally hazardous substance, liquid, n.o.s. (Oxytoclozanide)
Class	:	9
Packing group	:	III
Labels	:	Miscellaneous
Packing instruction (cargo aircraft)	:	964
Packing instruction (passenger aircraft)	:	964
Environmentally hazardous	:	yes

IMDG-Code

UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Oxytoclozanide)
Class	:	9
Packing group	:	III
Labels	:	9
EmS Code	:	F-A, S-F
Marine pollutant	:	yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Oxytoclozanide)
Class	:	9
Packing group	:	III
Labels	:	9
ERG Code	:	171
Marine pollutant	:	yes(Oxytoclozanide)

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
1.11	09/28/2024	5360093-00012	Date of first issue: 12/19/2019

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

ACGIH	: USA. ACGIH Threshold Limit Values (TLV)
CA AB OEL	: Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)
CA BC OEL	: Canada. British Columbia OEL
CA QC OEL	: Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants
ACGIH / TWA	: 8-hour, time-weighted average
CA AB OEL / TWA	: 8-hour Occupational exposure limit
CA BC OEL / TWA	: 8-hour time weighted average
CA QC OEL / TWA EV	: Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Develop-

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
1.11	09/28/2024	5360093-00012	Date of first issue: 12/19/2019

ment; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 09/28/2024
Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8